Evidence map›Paper›PMID 41416787›Full record

ArticleAntimicrobial agents and chemotherapy2026

Preclinical pharmacokinetics/pharmacodynamics studies defining the role of ethambutol in

Tawanda Gumbo, Gunavanthi D Boorgula, Shashikant Srivastava

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tawanda GumboNASOS Biotech, Dallas, Texas, USA.ORCID 0000-0001-7592-8012
Gunavanthi D BoorgulaDivision of Infectious Diseases, Department of Medicine, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
Shashikant SrivastavaDivision of Infectious Diseases, Department of Medicine, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA.ORCID 0000-0002-8786-8851

Funding

Short course combination regimens for treatment of Mycobacterium avium pulmonary disease: a translational bench-to-bedside approachR01AI179827 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI Shashi Kant · 2024 to 2026
$1.7M
Short course therapy for MDR-TB based on PK/PD answers for biological variabilityR56AI111985 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GUMBO, TAWANDA · 2014 to 2014
$900k
Reinforcing old warriors to treat Mycobacterium kansasii in shorter durationR21AI148096 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI KANT, SHASHI · 2020 to 2021
$413k
American Thoracic Foundation/INSMED Research Award in Non-Tuberculous Mycobacteria Lung DiseaseCystic Fibrosis Foundation Therapeutics KANT23G0National Institute of Allergy and Infectious Diseases 1R01AI179827, 1R21AI148096, AI111985NIAID NIH HHS R01 AI179827NIAID NIH HHS R21 AI148096NIAID NIH HHS R56 AI111985
6 · The paper itself

Abstract

Rifampin, isoniazid, and ethambutol are the backbone of the regimen used to treat

Indexed as

Antitubercular AgentsEthambutolLung DiseasesMycobacterium Infections, NontuberculousMycobacterium kansasiiHumansMicrobial Sensitivity TestsMonte Carlo MethodAntitubercular AgentsEthambutolcavitary concentrationsethambutol-resistancehollow fiber system model of Mycobacterium kansasii diseaseminimum inhibitory concentrationspharmacokinetics/pharmacodynamics

Identifiers

PMID41416787
PMCPMC12888887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.